ArticleTranslational cancer research2026
Development and internal validation of a multivariable prognostic prediction model in advanced breast cancer patients based on the SEER database.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A significant degree of contention persists regarding the optimal therapeutic approaches for managing individuals with advanced breast cancer. The objective of this study was to develop predictive models aimed at estimating the prognosis of patients and internally validating their predictive performance, as well as to precisely ascertain which subsets of patients would derive the most substantial benefits from specific treatment modalities, thereby enabling more personalized and effective therapeutic strategies. Methods: We retrospectively analyzed advanced breast cancer cases from the Surveillance, Epidemiology, and End Results (SEER) database (2010-2015) for prognostic model development and internal validation. Eligibility: female ≥15 years at diagnosis, histopathologically confirmed primary breast cancer, American Joint Committee on Cancer (AJCC) 6th Edition stage IIB, IIIA, IIIB, IIIC, or TxNxM1. Cases with incomplete data were excluded. The distribution of clinical characteristic variables and treatment modalities was evaluated using chi-squared tests. Kaplan-Meier univariate analysis and Cox proportional hazards regression analysis were performed to screen for prognostic variables that significantly influence overall survival and breast cancer-specific survival. We constructed the nomograms to evaluate the prognosis of patients using R version 4.2.0. and plotted receiver operating characteristic (ROC) curves, calibration curves and decision curve analysis (DCA) curves to comprehensively assess the predictive performance of these nomograms. Results: A total of 27,593 patients were ultimately included in our study cohort. We constructed nomograms to predict the prognosis of each subgroup of patients, which included clinical variables such as age, race, grade, T-stage, N-stage, surgery, radiation, chemotherapy, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, etc. The model exhibited robust performance: ROC curve analysis showed area under the curve (AUC) values exceeding 75% for 3-, 5-, and 10-year survival across all patient subsets. Calibration curves demonstrated excellent agreement between predicted and actual survival probabilities, confirming the model's reliability. DCA validated good clinical utility, as the model yielded higher net benefit within the target risk threshold range. Conclusions: This study provided accurate prognostic information of advanced breast cancer patients and constructed models which could provide a reference for clinicians in enabling personalized treatment among these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.